Alternate treatment options Although thrombolytics can produce dramatic responses for those patients who are eligible to receive treatment, the actual number of people who qualify for this therapy is ...
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...
Exercise-induced ST-segment depression ≥ 1.0 mm ≥ 1 episode of reversible ST-segment depression ≥ 1.0 mm during 48-hour ambulatory electrocardiographic (ECG) monitoring of routine activities. Patients ...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, ...
Performing open bypass surgery to restore circulation for people with a severe form of peripheral artery disease (PAD) -- a condition that limits blood flow to the legs and feet -- resulted in better ...
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality ...
Please provide your email address to receive an email when new articles are posted on . PARK CITY, Utah — Outcomes from the phase 1/2a HORNBILL study indicate a potential disease-modifying effect of ...
BioCardia ®, Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its ...
Treatment is determined by the type of stroke suffered (i.e., ischemic or hemorrhagic) rather than the anatomic location. Symptoms referable to the anterior circulation — specifically, anterior and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results